New drug combo shows promise for Hard-to-Treat sarcomas
NCT ID NCT02805725
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a combination of two chemotherapy drugs—trabectedin and cyclophosphamide—in 50 adults with advanced soft-tissue sarcomas that had already been treated. The goal was to find a safe dose and see if the combo could stop or slow tumor growth. Results showed the treatment was tolerable and helped some patients avoid progression for at least 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Trabectedin and cyclophosphamide
What this could lead to
If successful, this combination could offer a new treatment option to slow or stabilize advanced soft-tissue sarcomas that have not responded to prior therapies.
What could go wrong
This is an early-phase trial with only 50 participants, so results may not apply to all patients. Side effects from the drugs can be serious, and the benefit may be limited to a subset of sarcoma types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut Bergonié
Bordeaux, 33076, France